Preimplantation genetic testing market expected to reach $1.2 billion | Markets & Markets.

Chicago, December 18, 2023 (GLOBE NEWSWIRE) — Preimplantation genetic testing market According to the latest report released by MarketsandMarkets, revenue is expected to reach US$700 million in 2023 and US$1.2 billion by 2028, with a compound annual growth rate of 11.4% from 2023 to 2028. The growth of this market is mainly driven by the increasing number of fertility clinics across the world and advancements in genetic analysis technology. However, high procedural costs associated with preimplantation genetic testing may restrain market growth.

Download an illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=605

Preimplantation genetic testing market scope:

Reporting scope	detail
Market revenue in 2023	US$700 million
Estimated value in 2028	US$1.2 billion
growth rate	The compound annual growth rate is estimated to be 11.4%
Available market size	20212028
forecast period	20232028
forecast unit	Value (billions of dollars)
Reporting scope	Revenue forecasts, competitive landscape, growth factors and trends
Market segments covered	Program type, technology, product, application, cycle type and end user
Coverage area	North America, Europe, Asia Pacific and Rest of the World
Report Highlights	Updated player financial information/portfolio
Key market opportunities	Use of fertility treatment options by single parents and same-sex couples
Key market drivers	Declining fertility rate

Based on the type of surgery, the preimplantation genetic testing market is segmented into preimplantation genetic screening and preimplantation genetic diagnosis. The field of preimplantation genetic screening accounts for the largest share of the preimplantation genetic testing market. Much of this segment can be attributed to factors such as increased awareness and acceptance of genetic screening technology among prospective parents and increasing age of mothers.

On the basis of technology, the preimplantation genetic testing market is segmented into PCR, NGS, FISH, CGH, and SNP segments. The next-generation sequencing field is expected to dominate the preimplantation genetic testing market, driven by declining sequencing prices, rapidly increasing penetration of NGS in diagnostics, and increasing use of these systems by fertility clinics and research institutions for preimplantation genetic testing. Diagnostic and preimplantation genetic screening.

On the basis of products and services, the preimplantation genetic diagnosis and screening market is segmented into instruments, reagents and consumables, software, and services. In 2022, the reagents and consumables segment dominated the market. The majority of the market share of this segment can be attributed to the increasing number of preimplantation genetic diagnosis and preimplantation genetic screening procedures performed across the globe.

By region, the global preimplantation genetic testing market is segmented into North America, Europe, Asia Pacific, and Rest of the World. North America will hold the largest market share in 2022 owing to increasing government funding for genetic testing and declining fertility rates. Other factors driving the demand in the North American market include increasing infertility rates among women in the United States due to the rising prevalence of polycystic ovary syndrome (PCOS), increasing incidence of reproductive diseases such as chlamydia, and increasing age at first pregnancy.

Buy the Preimplantation Genetic Testing Industry Report (245-page PDF with insightful charts, tables, and figures): https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=605

The major players in the Preimplantation Genetic Testing market covered in the report are:

• Illumina, Inc. (USA)
• Thermo Fisher Scientific (USA)
• Agilent Technologies (USA)
• Revvity (USA)
• Cooper Company (USA)
• Abbott (USA)
• Takara Bio Inc. (Japan)
• QIAGEN (Germany)
• Vitrolife (Sweden)
• Oxford Nanopore Technologies Ltd (UK)
• Oxford Genomics Intellectual Property Ltd (UK)
• Yikang Gene (China)
• Shiva Sciences (India)
• Nanjing Chaonian Gene Technology Co., Ltd. (China)
• Medicover Genetics (Germany)
• Medical Genomics (India)
• Fugent Genetics (USA)
• Invicta Genetics (Poland)
• Genea Ltd (Australia)
• Scigene Corporation (USA)
• Bioarray SL (Spain)
• Youmei Biotechnology (Shanghai) Co., Ltd. (China)
• Jimai Biotechnology Co., Ltd. (China)
• Berry Genetics (China)
• Bangkok Genome Innovation Company (Thailand)
• And other

Request a free sample page: https://www.marketsandmarkets.com/requestsampleNew.asp?id=605

The research report divides the preimplantation genetic testing market into the following segments and sub-segments:

Regional division

• North America
• Europe
• Asia-Pacific
• Rest of the world

Program type split

• Preimplantation genetic screening
• preimplantation genetic diagnosis

technological fragmentation

• next generation sequencing
• polymerase chain reaction
• Fluorescence in situ hybridization
• comparative genomic hybridization
• single nucleotide polymorphism

product split

• Reagents and consumables
• instrument
• Software and Services

Application splitting

• Aneuploidy
• abnormal chromosome structure
• single gene disease
• X-linked diseases
• HLA typing
• gender identification

Cycle split type

• fresh non-donor
• Freeze non-donors
• new donor
• frozen donor

end user split

• fertility clinic
• Hospital
• diagnostic laboratory
• other end users

Get 10% free customization of this report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=605

The latest developments in the preimplantation genetic testing industry:

• In 2023, Thermo Fisher Scientific (USA) launched two new NGS-based test kits to support preimplantation genetic testing – aneuploidy (PGT-A), in vitro fertilization (IVF) and Intracytoplasmic sperm injection (ICSI) is commonly used in research.
• In 2022, The Cooper Companies, Inc. (USA) released PGT-Complete, which adds parental QC, genetic PN examination, and aneuploidy origin to the PGT-A test.
• In 2021, Vitrolife (Sweden) acquired Igenomix (Spain), a leader in reproductive genetic testing services mainly for IVF clinics.

Main market stakeholders:

• senior executive
• end user
• Finance/Purchasing Department
• R&D Department

Reporting objectives:

• Define, describe, segment and forecast the global preimplantation genetic testing market by procedure type, technology, product, application, cycle type, end user, and region.
• Provides detailed information on the major factors affecting market growth such as drivers, restraints, opportunities, and challenges.
• Micro markets are analyzed with respect to individual growth trends, prospects, and contribution to the overall Preimplantation Genetic Testing market.
• Analyze market opportunities for stakeholders and provide key players with detailed information on the competitive landscape.
• To project the segment market size in four regions: North America, Europe, Asia Pacific, and Rest of the World.
• Profile the key players and provide a comprehensive analysis of their product portfolio, market position and core capabilities.
• Market players are benchmarked using a proprietary Competitive Leadership Map framework that analyzes market players on various parameters within broad categories of business and product excellence.

Related reports:

Ultrasound market

Digital PCR (dPCR) and real-time PCR (qPCR) market

Next Generation Sequencing (NGS) Market

In vitro fertilization market

Infertility treatment market

Research insights: https://www.marketsandmarkets.com/ResearchInsight/preimplantation-genic-testing-market.asp

Content source: https://www.marketsandmarkets.com/PressReleases/preimplantation-genic-testing.asp